Abstract

Neurofilaments: towards application in clinical practice

1. Do neurofilaments predict MS disease course?

Mark Freedman

3. Quantifying therapy response in MS by neurofilaments?

Jens Kuhle

3. Neurofilament applications outside the MS field

Roberto Furlan

Abstract

Neurofilaments are in late stage development as biomarkers for numerous neurological disorders, including MS. Their interpretation, their diagnostic, prognostic, monitoring value have to be established empirically but also through the understanding of their biology, mechanisms of release, kinetic. Data taken from several different diseases and experimental settings, including Alzheimer’s Disease, Parkinson’s Disease, amyotrophic lateral sclerosis, peripheral neuropathies, stroke, experimental cardiac arrest, bipolar disorder, and even COVID-19 will be discussed in order to assess potentialities, limits, confounding factors, perspectives of a biomarker that has raised huge interests and re-ignited the field of biological fluid biomarkers in neurology, but might require still more in depth knowledge to be correctly used and interpreted.